Akinetonum – protivoparkinsonichesky drug.

Parkinson's Syndrome: treatment of symptoms of Parkinson's disease, such as rigidity, tremor.

Extrapyramidal symptoms caused by neuroleptics or to similarly operating drugs.

Poisoning with nicotine or phosphorus-containing organic substances.

Structure

• active ingredient: biperiden;
Biperidinum of a lactate of 5 mg contains
• 1 ml of solution that corresponds to 3.88 mg of Biperidinum of the basis;
• other components: sodium a lactate, water for injections.

Contraindication

Increased individual sensitivity to medicament components, closed-angle glaucoma, mechanical narrowing (stenosis) of digestive tract, megacolon, obstruction of digestive tract.

Side reactions

Infection and invasion. Frequency is unknown: parotitis.

Disturbance of the immune system. Very seldom: hypersensitivity to drug.

Mental disturbances. Seldom: at use of high doses – agitation, excitement, fear, confusion of consciousness, a delirium, a hallucination, insomnia. Very seldom: nervousness, euphoria.

Disturbance of nervous system. Seldom: fatigue, dizziness and memory impairment. Very seldom: headaches, dyskinesia, an ataxy and speech disturbances, the increased tendency to epileptic attacks and spasms.

Disturbance of organs of sight. Very seldom: accommodation disturbance, mydriasis, photosensitivity. There can be closed-angle glaucoma (it is necessary to check intraocular pressure).

Disturbance of a cardiovascular system. Seldom: tachycardia. Very seldom: bradycardia. After parenteral use of medicament the falling of the ABP is possible.

Disturbance of digestive system. Seldom: dryness in a mouth, nausea, indigestions. Very seldom: constipation.

Disturbance of skin and hypodermic fabrics.

Route of administration

Dosage of Biperidinum should be selected individually.

parkinsonism Syndrome.

In an initiation of treatment with the dose 10–20 mg of the medicament Akinetonum (2–4 ml of solution for the injections) divided into several injections, entered intramusculary or in the form of slow intravenous injections during the day.

Extrapyramidal symptoms caused by effect of medicines.

2.5-5 mg of Akinetonum (0.5-1 ml of solution for injections) in the form of the single dose entered intramusculary or in the form of a slow intravenous injection. If necessary the same dosage can be entered repeatedly in 30 min. The highest general daily dose makes 10–20 mg of the medicament Akinetonum (2–4 ml of solution for injections).

1 mg (0.2 ml) of the medicament Akinetonum aged from 1 up to 6 years – 2 mg (0.4 ml) and from 6 to 10 years – 3 mg (0.6 ml).

Poisoning with nicotine.

Intramuscular introduction of 5-10 mg (1-2 ml). In especially hard cases it is recommended to add usual therapeutic measures with intravenous administration of 5 mg of medicament (1 ml of solution for injections).

In poisoning with phosphorus-containing organic substances the dosage of the medicament Akinetonum is defined by

individually. Depending on toxicity degree the medicament needs to be administered intravenously repeatedly (a dosage - 5 mg) until symptoms of poisoning disappear. If symptoms disappear during an injection, it should be stopped.

Use during pregnancy or feeding by a breast

As experience of use of Akinetonum during pregnancy is limited to

Feature of use

Anticholinergic medicaments can inhibit a lactation. The medicament Akinetonum is removed with breast milk therefore it is necessary to refuse feeding by a breast.

Data on influence of the medicament Akinetonum on reproductive function are absent.

Experience of use of Biperidinum to children is limited to

. Drug more often was appointed during the limited span in the dystonia caused by medicines (for example, neuroleptics or Metoclopramidum and similar drugs) that can arise as side effect or a symptom of intoxication.

Ability to influence speed of response at control of motor transport or other mechanisms

Because of side effects from the central and peripheral nervous system, such as fatigue, dizziness and drowsiness, even at the correct use this medicament can influence speed of response in such a way that irrespective of the restriction caused by a basic disease the ability to participate actively in traffic or to work with the electric tools or tools equipped with engines, and other mechanisms can be even more broken.

Overdose

Symptoms: similar to signs of toxicity of atropine with peripheral anticholinergic signs: the mydriatic pupils which are slowly reacting to light (mydriasis), dryness of mucous membranes, face reddening, increase in frequency of a warm rhythm, an atony of a bladder and intestines, temperature increase and disturbances (such as excitement, nonsense, a disorientation, loss of memory and/or a hallucination). At heavy toxicity there is a risk of cardiac arrest and failure of a respiratory system.

Treatment: intake of inhibitors of acetylcholinesterase and first of all physostigmine which can get into cerebrospinal fluid and also influences symptoms of the central genesis (and/or salicylate physostigmine in case of positive test for physostigmine). If necessary support of function of cardiovascular and respiratory systems (artificial oxygenotherapy), febrifuges (at fervescence), bladder catheterization – depending on type of symptoms.

Interaction with other medicines and other types of interactions

Use of the medicament Akinetonum together with other anticholinergic psychotropic medicines, antihistaminic, protivoparkinsonichesky and spasmolytic medicines can cause strengthening of the central and peripheral side effects. The concomitant use of quinidine can cause strengthening of anticholinergic cardiovascular effects (especially disturbances of atrioventricular conductivity). Simultaneous use with a levodopa can strengthen dyskinesia. At simultaneous use of Biperidinum and medicaments of a levodopa / karbidopy at patients with Parkinson's disease observed generalized choreiform disturbances of the movement. The late dyskinesia caused by neuroleptics can amplify under the influence of the medicament Akinetonum. Parkinsonism symptoms in the presence of late dyskinesia can sometimes be so serious that treatment by anticholinergic medicaments becomes necessary. Anticholinergics can enhance the central side effects of pethidine. At medicament treatment, effects of alcohol therefore it is necessary to avoid alcohol intake can amplify. Akinetonum weakens effect of Metoclopramidum and other operating connections having similar effect on digestive tract.

to Store

out of children's reach at a temperature not over 25 With in original packing.